{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:19:49Z","timestamp":1785521989540,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uveitis is a major cause of blindness in developed countries, and adverse effects associated with long-term use of topical or systemic steroids and immunosuppressive agents are notable. This study aimed to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in sarcoidosis-associated uveitis (SAU) and idiopathic uveitis (IdU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This monocentric retrospective study included 42 patients with SAU and 15 patients with IdU treated with HCQ for at least six months between March 2003 and December 2022. All types of uveitis were included. Most patients had chronic bilateral granulomatous SAU or IdU. Efficacy was determined by the success rate of HCQ at 6 and 12 months, and at the last visit and was defined as having control of inflammation, no more than 5\u00a0mg prednisone daily and less than or equal to 2 drops of dexamethasone phosphate 0.1%, and no treatment failure due to safety. Biomicroscopic data, best-corrected visual acuity, inflammation grading (SUN criteria) and optionally data from optical coherence tomography and fluorescein or indocyanine green angiography were assessed. The Fisher\u2019s exact test and the Wilcoxon rank test were used for the comparison of qualitative data and quantitative data respectively. Prednisone dose was compared using a mixed model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median [IQR] duration to the last visit was 19.5 [11-44.8] months in SAU patients and 18 [13\u201338] months in IdU patients. At the last visit, 55% of patients with SAU (including 70% of anterior SAU and 77% of intermediate SAU) and 40% patients with IdU (including 27% of anterior IdU) were successfully treated with HCQ ; the median [IQR] prednisone dose decreased from 10 [8.0-27.5] to 4 [2.5\u20135.75] mg\/day and from 15.5 [12.5\u201319.5] to 3.0 [3.0\u20135.0] mg\/day in SAU and IdU patients, respectively. The reduction in median prednisone dose was significant in patients with SAU (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). The incidence rate ratio of flare was 0.73 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.143) in SAU patients and 0.26 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in IdU patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HCQ could be an interesting therapeutic option for specific types of SAU and IdU. Additionally, HCQ decreased the incidence of flare-ups and the need for oral prednisone in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-026-00598-7","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T14:04:34Z","timestamp":1779977074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxychloroquine in the treatment of sarcoidosis-associated uveitis and idiopathic uveitis"],"prefix":"10.1186","volume":"16","author":[{"given":"Sarah","family":"Plavonil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Jacquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Jamilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Seve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"El-Jammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"598_CR1","doi-asserted-by":"crossref","unstructured":"Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C et al (2018) A Focus on the Epidemiology of Uveitis. Ocular Immunology and Inflammation, Taylor and Francis Ltd, 26;pp 2\u201316","DOI":"10.1080\/09273948.2016.1196713"},{"key":"598_CR2","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Aparicio \u00c1, Garc\u00eda de Y\u00e9benes MJ, Ot\u00f3n T, Mu\u00f1oz-Fern\u00e1ndez S (2021) Prevalence and Incidence of Uveitis: A Systematic Review and Meta-analysis. Ophthalmic Epidemiology, vol 28. Taylor and Francis Ltd., pp 461\u2013468","DOI":"10.1080\/09286586.2021.1882506"},{"issue":"9","key":"598_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/bjo.80.9.844","volume":"80","author":"MS Suttorp-Schulten","year":"1996","unstructured":"Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80(9):844\u2013848","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"598_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","volume":"88","author":"OM Durrani","year":"2004","unstructured":"Durrani OM (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159\u20131162","journal-title":"Br J Ophthalmol"},{"key":"598_CR5","unstructured":"S\u00e8ve P, Bodaghi B, Trad S, Sellam J, Bellocq D, Bielefeld P et al (2018) Uveitis: Diagnostic work-up. Elsevier Masson SAS 39:676\u2013686Revue de Medecine InterneAvailable from: Uveitis: Diagnostic work-up. Recommendations from an expert committe Recommendations from an expert committee [Internet]"},{"key":"598_CR6","doi-asserted-by":"crossref","unstructured":"Giorgiutti S, Jacquot R, El Jammal T, Bert A, Jamilloux Y, Kodjikian L et al (2077) Sarcoidosis-related uveitis: a review. J Clin Med [Internet]. 2023 Apr 29 [cited 2023 May 19];12(9):3194. Available from: https:\/\/www.mdpi.com\/-0383\/12\/9\/3194","DOI":"10.3390\/jcm12093194"},{"key":"598_CR7","doi-asserted-by":"crossref","unstructured":"Bertrand PJ, Jamilloux Y, Ecochard R, Richard-Colmant G, Gerfaud-Valentin M, Guillaud M Uveitis: Autoimmunity\u2026 and beyond [Internet]. Vol. 18, Autoimmunity Reviews., Elsevier BV et al (2019) [cited 2023 Feb 21]. p. 102351. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S156899721930151X?via%3Dihub","DOI":"10.1016\/j.autrev.2019.102351"},{"key":"598_CR8","doi-asserted-by":"crossref","unstructured":"S\u00e8ve P, Cacoub P, Bodaghi B, Trad S, Sellam J, Bellocq D et al (2017) Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmunity Reviews, vol 16. Elsevier B.V., pp 1254\u20131264","DOI":"10.1016\/j.autrev.2017.10.010"},{"issue":"2","key":"598_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/09273948.2013.855799","volume":"23","author":"NP Jones","year":"2015","unstructured":"Jones NP (2015) The Manchester Uveitis Clinic: The First 3000 Patients\u2014Epidemiology and Casemix. Ocul Immunol Inflamm 23(2):118\u2013126","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"598_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1750-1172-7-57","volume":"7","author":"T Barisani-Asenbauer","year":"2012","unstructured":"Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H (2012) Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis 7(1):57","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"598_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1076\/ocii.11.4.287.18270","volume":"11","author":"S Oruc","year":"2003","unstructured":"Oruc S, Kaplan AD, Galen M, Kaplan HJ (2003) Uveitis referral pattern in a Midwest University Eye Center. Ocul Immunol Inflamm 11(4):287\u2013298","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"598_CR12","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10792-021-01791-4","volume":"41","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Kaburaki T, Tanaka R, Shirahama S, Komae K, Nakahara H et al (2021) Incidence and changing patterns of uveitis in Central Tokyo. Int Ophthalmol 41(7):2377\u20132388","journal-title":"Int Ophthalmol"},{"issue":"6","key":"598_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1442-9071.2009.02102.x","volume":"37","author":"H Keino","year":"2009","unstructured":"Keino H, Nakashima C, Watanabe T, Taki W, Hayakawa R, Sugitani A et al (2009) Frequency and clinical features of intraocular inflammation in Tokyo. Clin Exp Ophthalmol 37(6):595\u2013601","journal-title":"Clin Exp Ophthalmol"},{"key":"598_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ajo.2018.10.018","volume":"198","author":"RY Choi","year":"2019","unstructured":"Choi RY, Rivera-Grana E, Rosenbaum JT (2019) Reclassifying Idiopathic Uveitis: Lessons From a Tertiary Uveitis Center. Am J Ophthalmol 198:193\u2013199","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"598_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/09273948.2018.1522356","volume":"27","author":"G Richard Colmant","year":"2019","unstructured":"Richard Colmant G, Kodjikian L, De Parisot De Bernecourt A, Guillaud M, Gerfaud-Valentin M, Denis P et al (2019) Uveitis of Unknown Etiology: Clinical and Outcome features. A Retrospective Analysis of 355 Patients. Ocul Immunol Inflamm 27(8):1251\u20131258","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"598_CR16","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.ophtha.2017.06.017","volume":"124","author":"EB Suhler","year":"2017","unstructured":"Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A et al (2017) Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. Ophthalmology 124(12):1799\u20131807","journal-title":"Ophthalmology"},{"key":"598_CR17","doi-asserted-by":"crossref","unstructured":"Lee K, Bajwa A, Freitas-Neto CA, Metzinger JL, Wentworth BA, Foster CS (2014) A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: Part II. Expert Opinion on Biological Therapy. Informa Healthcare. 14;pp 1651\u20131666","DOI":"10.1517\/14712598.2014.947957"},{"issue":"6","key":"598_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","volume":"128","author":"EB Suhler","year":"2021","unstructured":"Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD et al (2021) Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology 128(6):899\u2013909","journal-title":"Ophthalmology"},{"issue":"9","key":"598_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","volume":"55","author":"OP Sharma","year":"1998","unstructured":"Sharma OP (1998) Effectiveness of Chloroquine and Hydroxychloroquine in Treating Selected Patients With Sarcoidosis With Neurological Involvement. Arch Neurol 55(9):1248\u20131254","journal-title":"Arch Neurol"},{"issue":"1","key":"598_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1440-1843.1997.tb00056.x","volume":"2","author":"JM HILTON","year":"1997","unstructured":"HILTON JM, COOPER DM, HENRY RL (1997) Hydroxychloroquine therapy of diffuse pulmonary sarcoidosis in two Australian male children. Respirology 2(1):71\u201374","journal-title":"Respirology"},{"issue":"1","key":"598_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/01676830.2010.524268","volume":"30","author":"MP Rabinowitz","year":"2011","unstructured":"Rabinowitz MP, Murchison AP (2011) Orbital Sarcoidosis Treated With Hydroxychloroquine. Orbit 30(1):13\u201315","journal-title":"Orbit"},{"issue":"4","key":"598_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0248-8663(05)82491-9","volume":"14","author":"Y Mathis Ch, Maugars","year":"1993","unstructured":"Mathis Ch, Maugars Y, Vilon Ph, Prost A (1993) Hypercalc\u00e9mie majeure r\u00e9v\u00e9latrice d\u2019une sarco\u00efdose. Rev Med Interne 14(4):249\u2013521","journal-title":"Rev Med Interne"},{"key":"598_CR23","doi-asserted-by":"crossref","unstructured":"Jamilloux Y, Jammal T, El, Bert A, S\u00e8ve P (2022) Mouvement th\u00e9rapeutique-La Revue de M\u00e9decine Interne L\u2019hydroxychloroquine pour la sarco\u00efdose extra-pulmonaire non-s\u00e9v\u00e8re Hydroxychloroquine for non-severe extra-pulmonary sarcoidosis","DOI":"10.1016\/j.revmed.2022.04.030"},{"key":"598_CR24","doi-asserted-by":"crossref","unstructured":"Hu Y, Li Z, Chen G, Li Z, Huang J, Huang H et al (2022) Hydroxychloroquine Alleviates EAU by Inhibiting Uveitogenic T Cells and Ameliorating Retinal Vascular Endothelial Cells Dysfunction. Front Immunol. ;13","DOI":"10.3389\/fimmu.2022.859260"},{"key":"598_CR25","doi-asserted-by":"crossref","unstructured":"Bert A, El Jammal T, Kodjikian L, Gerfaud-Valentin M, Jamilloux Y, Seve P (2023) Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis. Ocul Immunol Inflamm","DOI":"10.1080\/09273948.2023.2165952"},{"key":"598_CR26","doi-asserted-by":"crossref","unstructured":"Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am J Ophthalmol (2005) ;140(3):509\u201316","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"598_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajo.2017.03.029","volume":"178","author":"A de Parisot","year":"2017","unstructured":"de Parisot A, Kodjikian L, Errera MH, Sedira N, Heron E, P\u00e9rard L et al (2017) Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). Am J Ophthalmol 178:176\u2013185","journal-title":"Am J Ophthalmol"},{"key":"598_CR28","doi-asserted-by":"crossref","unstructured":"Grumet P, Kodjikian L, de Parisot A, Errera MH, Sedira N, Heron E et al (2018) Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: Clinical and medicoeconomic evaluation of a standardized strategy of the etiological diagnosis). Autoimmunity Reviews. Elsevier B.V., 17;pp 331\u2013343","DOI":"10.1016\/j.autrev.2017.10.018"},{"key":"598_CR29","doi-asserted-by":"crossref","unstructured":"Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA (2019) Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol 103(10):1418\u20131422","DOI":"10.1136\/bjophthalmol-2018-313356"},{"issue":"2","key":"598_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"ATS\/ERS\/WASOG","year":"1999","unstructured":"ATS\/ERS\/WASOG (1999) Statement on Sarcoidosis. Am J Respir Crit Care Med 160(2):736\u2013755","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"598_CR31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/art.20839","volume":"51","author":"S Abad","year":"2004","unstructured":"Abad S, Meyssonier V, Allali J, Gouya H, Giraudet AL, Monnet D et al (2004) Association of peripheral multifocal choroiditis with sarcoidosis: A study of thirty-seven patients. Arthritis Care Res (Hoboken) 51(6):974\u2013982","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"598_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","volume":"228","author":"SUN working group","year":"2021","unstructured":"SUN working group (2021) Classification Criteria for Sarcoidosis-Associated Uveitis. Am J Ophthalmol 228:220\u2013230","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"598_CR33","first-page":"793","volume":"11","author":"JL Dufier","year":"1988","unstructured":"Dufier JL (1988) [The Monoyer\u2019s decimal scale]. J Fr Ophtalmol 11(11):793","journal-title":"J Fr Ophtalmol"},{"key":"598_CR34","doi-asserted-by":"crossref","unstructured":"Hysa E, Cutolo CA, Gotelli E, Pacini G, Schenone C, Kreps EO et al (2021) Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update. European Journal of Clinical Investigation, vol 51. John Wiley and Sons Inc","DOI":"10.1111\/eci.13572"},{"key":"598_CR35","doi-asserted-by":"crossref","unstructured":"Bansal R, Gupta A (2020) Protein Biomarkers in Uveitis. Frontiers in Immunology, vol 11. Frontiers Media S.A.","DOI":"10.3389\/fimmu.2020.610428"},{"key":"598_CR36","unstructured":"Calder VL, Shaer B, Muhaya M, Mclauchlan M, Pearson RV, Jolly G et al Increased CD4 Expression and Decreased IL-10 in the Anterior Chamber in Idiopathic Uveitis"},{"key":"598_CR37","doi-asserted-by":"crossref","unstructured":"Manohar BB, Rathinam SR (2010) Intermediate uveitis. Indian Journal of Ophthalmology. Wolters Kluwer -- Medknow, pp 21\u201327","DOI":"10.4103\/0301-4738.58469"},{"issue":"3","key":"598_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0039-6257(01)00275-2","volume":"46","author":"SR Boyd","year":"2001","unstructured":"Boyd SR, Young S, Lightman S (2001) Immunopathology of the Noninfectious Posterior and Intermediate Uveitides. Surv Ophthalmol 46(3):209\u2013233","journal-title":"Surv Ophthalmol"},{"key":"598_CR39","doi-asserted-by":"crossref","unstructured":"Prete M, Dammacco R, Fatone MC, Racanelli V (2016) Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Vol. 16, Clinical and Experimental Medicine. Springer-Verlag Italia s.r.l.; pp. 125\u201336","DOI":"10.1007\/s10238-015-0345-6"},{"issue":"1","key":"598_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/bjo-2024-325163","volume":"109","author":"M Leclercq","year":"2025","unstructured":"Leclercq M, S\u00e8ve P, Biard L, Vautier M, Maalouf G, Leroux G et al (2025) Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis. Br J Ophthalmol 109(1):34\u201340","journal-title":"Br J Ophthalmol"},{"key":"598_CR41","doi-asserted-by":"crossref","unstructured":"Takase H, Acharya NR, Babu K, Bodaghi B, Khairallah M, McCluskey PJ et al (2021) Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis. British Journal of Ophthalmology. ;105(11):1515\u20139","DOI":"10.1136\/bjophthalmol-2020-317354"},{"key":"598_CR42","doi-asserted-by":"crossref","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R, Br\u00e9zin AP, Chee SP et al (2018) Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Vol. 125, Ophthalmology. Elsevier Inc., pp 757\u2013773","DOI":"10.1016\/j.ophtha.2018.03.005"},{"key":"598_CR43","doi-asserted-by":"crossref","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Atmaca LS, Becker MD, Brezin AP et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. ;140(3):509\u201316","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"598_CR44","doi-asserted-by":"crossref","unstructured":"Doyno C, Sobieraj DM, Baker WL (2020) Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clinical Toxicology, vol 59. Taylor and Francis Ltd.","DOI":"10.1080\/15563650.2020.1817479"},{"issue":"11","key":"598_CR45","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/bjophthalmol-2018-313350","volume":"103","author":"ST Garrity","year":"2019","unstructured":"Garrity ST, Jung JY, Zambrowski O, Pichi F, Su D, Arya M et al (2019) Early hydroxychloroquine retinopathy: Optical coherence tomography abnormalities preceding Humphrey visual field defects. Br J Ophthalmol 103(11):1600\u20131604","journal-title":"Br J Ophthalmol"},{"key":"598_CR46","doi-asserted-by":"crossref","unstructured":"Yusuf IH, Sharma S, Luqmani R, Downes SM (2017) Hydroxychloroquine retinopathy. Vol. 31, Eye (Basingstoke). Nature Publishing Group, pp 828\u2013845","DOI":"10.1038\/eye.2016.298"},{"issue":"4","key":"598_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/0961203317734922","volume":"27","author":"K Tselios","year":"2018","unstructured":"Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB (2018) Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus 27(4):591\u2013599","journal-title":"Lupus"},{"issue":"11","key":"598_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.autrev.2011.04.029","volume":"10","author":"L Arnaud","year":"2011","unstructured":"Arnaud L, Zahr N, Costedoat-Chalumeau N, Amoura Z (2011) The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev 10(11):674\u2013678","journal-title":"Autoimmun Rev"},{"issue":"2","key":"598_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cpt.1194","volume":"106","author":"N Costedoat-Chalumeau","year":"2019","unstructured":"Costedoat-Chalumeau N, Houssiau F, Izmirly P, Guern V, Le, Navarra S, Jolly M et al (2019) A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring\u2009<\u2009scp>SLE: Assessment by Drug Levels and Self\u2010Administered Questionnaires. Clin Pharmacol Ther 106(2):374\u2013382","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"598_CR50","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P et al (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54(10):3284\u20133290","journal-title":"Arthritis Rheum"},{"issue":"11","key":"598_CR51","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1136\/bjophthalmol-2018-313133","volume":"103","author":"P Chauvelot","year":"2019","unstructured":"Chauvelot P, Skanjeti A, Jamilloux Y, De Parisot A, Broussolle C, Denis P et al (2019) 18F-fluorodeoxyglucose positron emission tomography is useful for the diagnosis of intraocular sarcoidosis in patients with a normal CT scan. Br J Ophthalmol 103(11):1650\u20131655","journal-title":"Br J Ophthalmol"},{"key":"598_CR52","doi-asserted-by":"crossref","unstructured":"Gupta A, Sharma A, Bansal R, Sharma K (2015) Classification of intraocular tuberculosis. Ocular Immunology and Inflammation, vol 23. Informa Healthcare, pp 7\u201313","DOI":"10.3109\/09273948.2014.967358"},{"key":"598_CR53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2021.03.040","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"Standardization of Uveitis Nomenclature (SUN) Working Group (2021) Classification Criteria for Tubercular Uveitis. Am J Ophthalmol 228:142\u2013151","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"598_CR54","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/bjophthalmol-2021-318868","volume":"107","author":"W Danjou","year":"2023","unstructured":"Danjou W, Pradat P, Jamilloux Y, Gerfaud-Valentin M, Kodjikian L, Trad S et al (2023) Usefulness of the QuantiFERON test for the diagnosis of tubercular uveitis and the predictions of response to antituberculosis treatment. Br J Ophthalmol 107(4):500\u2013504","journal-title":"Br J Ophthalmol"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-026-00598-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-026-00598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-026-00598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:10:08Z","timestamp":1785517808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-026-00598-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s12348-026-00598-7","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study received approval from the local ethics committee (Comit\u00e9s de Protection des Personnes Sud Est IV) in February 2019 (N\u00b0 19\u201331) and was registered on\n                      \n                      (NCT03877575). According to French law, this study did not require written informed consent due to its retrospective nature, and patient management was not modified (D\u00e9lib\u00e9ration n\u00b0 2018\u2009\u2212\u2009155 du 3 mai 2018 ).","order":1,"name":"Ethics","label":"Ethic approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"37"}}